Pharma BD Deal Intelligence
Fresenius Kabi's $3.7B acquisition of APP Pharmaceuticals gave it a leading US position in sterile injectable generics that remains a core, continuously-invested-in platform today. The deal's own contingent earnout expired worthless in 2011 after missing its EBITDA growth target, though the underlying business became a major profit driver once US injectable shortages hit around 2012.
APP gave Fresenius Kabi its US foothold and became a core, still-operating platform, but the deal's own earnout targets were missed and legacy plants drew FDA warning letters before recovering.
Full analysis, sources & comparables →Fresenius chairman Ulf Mark Schneider: "APP is a fast-growing, highly profitable company with a strong management team that has an excellent market position in…
CNBC reported $3.7B base deal with up to $970M CVR ($6/share contingent on 2008-2010 EBITDA targets), characterizing the transaction as Fresenius's largest…
Schneider: "We are pleased to be able to complete this major transaction in a very short time... Through APP, Fresenius Kabi enters the U.S. pharmaceuticals…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
$23/share cash + CVR up to $970M ($4.6B with CVR; up to $5.6B with assumed debt); injectable generics; closed Sep 10 2008
APP gave Fresenius Kabi its US foothold and became a core, still-operating platform, but the deal's own earnout targets were missed and legacy plants drew FDA warning letters before recovering.
Assessment window: 15yr post-close.
Hospital injectable generics are off-patent sterile parenteral drugs — oncology cytotoxics, antibiotics/anti-infectives, anesthetics, analgesics and ICU medications — supplied to acute-care providers. The category is supply-chain critical, capacity-constrained, and prone to shortages because sterile manufacturing is costly and barriers to entry deter new generic entrants.
By 2008 the US sterile injectable generics segment was concentrated among Hospira (the former Abbott Hospital Products spinout, market leader), Teva (post-SICOR), Sandoz (Novartis generics), Mayne Pharma (acquired by Hospira 2007) and APP Pharmaceuticals — a Patrick Soon-Shiong-led specialist with 100+ hospital products and US manufacturing in Illinois, New York and Puerto Rico. Fresenius Kabi was the European injectable leader (clinical nutrition, IV fluids, oncology generics) but had no US franchise. The $3.7B base / up-to-$5.6B (with debt and CVR) APP acquisition vaulted Fresenius into the #2 global injectable position and gave it instant US scale in oncology and critical-care injectables. Soon-Shiong characterized the combination as enabling 'rapid globalization of APP's portfolio' through Fresenius infrastructure. The CVR of up to $970M ($6/share) tied incremental consideration to APP hitting EBITDA targets through 2010, signaling Fresenius's confidence in volume growth from chronic shortages and biosimilar/biologic injectable pipeline upside. Closed September 10, 2008 at $23/share cash plus the CVR, the deal redrew the global hospital-injectable map.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Fresenius SE / Fresenius Kabi / APP Pharmaceuticals, Inc. (this deal) | 2008 | $3.7B | 67 |
| ViroPharma Incorporated / Lev Pharmaceuticals, Inc. | 2008 | $443M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Alkermes plc / Cephalon, Inc. (Vivitrol rights) | 2008 | $27M | 83 |
| Sanofi-Aventis / Symbion Consumer (Primary Health Care) | 2008 | $544M | 71 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2008 | $8.8B | 68 |
← Browse all deals · How we score deals
More: 2008 deals